Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

2024; Elsevier BV; Volume: 211; Linguagem: Inglês

10.1016/j.ejca.2024.114296

ISSN

1879-0852

Autores

Martin Reck, Tudor‐Eliade Ciuleanu, Michael Schenker, Stéphanie Bordenave-Juchereau, Manuel Cobo, Óscar Juan, Niels Reinmuth, Eduardo Richardet, Enriqueta Felip, J. Menezes, Ying Cheng, Hideaki Mizutani, Bogdan Żurawski, Aurelia Alexandru, David P. Carbone, Shun Lu, Thomas John, Takekazu Aoyama, Diederik J. Grootendorst, Nan Hu, Laura J. Eccles, Luis Paz‐Ares,

Tópico(s)

Lung Cancer Treatments and Mutations

Resumo

We report 5-year efficacy and safety outcomes from CheckMate 9LA in patients with metastatic non-small cell lung cancer (mNSCLC) and exploratory analyses in key patient subgroups.

Referência(s)